The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients

Journal of Endocrinological Investigation

Volumn 29, Issue 11, 2006, Pages 957-961

  Negro, Rob ^a   Formoso, G ^a   Hassan, H ^b  

^a AUSL LE/1   (Italy)

^b RIPAS HOSPITAL   (Brunei Darussalam)

Author keywords

Adiponectin; ARB; Hypertension; Insulin resistance

Indexed keywords

ADIPONECTIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN; TELMISARTAN; TRIACYLGLYCEROL; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ADULT; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED;

ADIPONECTIN; ADULT; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TRIGLYCERIDES;

EID: 33846976548     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349207     Document Type: Article

References (34)

1. Abbasi F, Chu JW, Lamendola C, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004, 53: 585-90.
2. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secrection from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002, 87: 5662-7.
3. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 13: 1457-62.
4. Yusuf S, Gerstein H, Hoogwerf B, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001, 286: 1882-5.
5. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42: 76-81.
6. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of Telmisartan. Diabetes Care 2004, 27: 1015.
7. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005, 4: 6-13.
8. Benson C, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004, 43: 993-1002.
9. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997, 100: 3149-53.
10. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994, 37: 843-5.
11. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981, 30: 387-92.
12. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relatioship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000, 23: 171-5.
13. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004, 27: 457-64.
14. Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999, 107: 133-9.
15. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990, 13: 1109-11.
16. Higashiura K, Ura N, Takada T, et al. The effect of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000, 13: 290-7.
17. Togashi N, Ura N, Higashiura K, Murakami H, Simamoto K. The contribution of skeletal muscle tumor necrosis factor-to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000, 18: 1605-10.
18. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40: 609-11.
19. Bogan JS, Lodish HF. Two compatments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 1999, 146: 609-20.
20. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-9.
21. Rosen E, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4: 611-7.
22. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003, 52: 283-90.
23. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7: 947-53.
24. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13: 84-9.
25. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26: 172-8.
26. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005, 70: 20-5.
27. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 2006, 8: 19-28.
28. Verstraete M. Value and limitation of meta-analysis. Pathophysiol Haemost Thromb 2002, 32: 278-81.
29. Tan KCB, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004, 89: 765-9.
30. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003, 8: 71-86.
31. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32: 47-50.
32. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278: 45021-6.
33. Dandona P. Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions. Diabetes Technol Ther 2002, 4: 809-15.
34. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107: 671-4.